Journal of Clinical Oncology, Vol 12, 2086-2093, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group

M Schumacher, G Bastert, H Bojar, K Hubner, M Olschewski, W Sauerbrei, C Schmoor, C Beyerle, RL Neumann and HF Rauschecker
Institut fur Medizinische Biometrie und Informatik, Universitat Freiburg, Germany.

PURPOSE: In 1984, the German Breast Cancer Study Group (GBSG) started a multicenter randomized clinical trial to compare the effectiveness of three versus six cycles of 500 mg/m2 cyclophosphamide, 40 mg/m2 methotrexate, and 600 mg/m2 fluorouracil (CMF) on day 1 and 8 starting perioperatively with or without tamoxifen (TAM) (3 x 10 mg/d for 2 years). The aim of the trial was to compare recurrence-free and overall survival between the different treatment modalities. PATIENTS AND METHODS: During 5 years, 41 institutions randomized 473 patients (3 x CMF: 145; 3 x CMF + TAM: 93; 6 x CMF 144; 6 x CMF + TAM: 91). Until March 31, 1992, median follow-up time was 56 months with 197 events for disease-free survival and 116 deaths observed. This provides a power of approximately 80% to detect a potential treatment difference corresponding to a relative risk (RR) of 0.67 for recurrence-free survival. Treatment modalities and various patient characteristics were evaluated by means of a multivariate Cox regression analysis. RESULTS: No significant difference in recurrence-free survival was observed with respect to hormonal therapy (RR = 0.75 TAM v no TAM; 95% confidence interval [CI], 0.54 to 1.04; P = .08) as well as duration of chemotherapy (RR = 0.90 of 6 x CMF v 3 x CMF; 95% CI, 0.67 to 1.19; P = .45). Similar results were obtained for overall survival. The multivariate analysis revealed a significant prognostic impact of the number of positive lymph nodes and the progesterone receptor level on recurrence-free survival. Compliance with chemotherapy within the range of 85% to 115% of the target dose was achieved in 94% and 78% of the patients randomized to 3 x CMF and 6 x CMF, respectively. Sufficient compliance with TAM was reported for 141 patients (93%). CONCLUSION: At this stage of follow-up, six courses of CMF are not superior to three courses with respect to recurrence-free survival.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Hothorn, P. Buhlmann, S. Dudoit, A. Molinaro, and M. J. Van Der Laan Survival ensembles Biostat., July 1, 2006; 7(3): 355 - 373. [Abstract] [Full Text] [PDF]

				M. Kaufmann, E. Graf, W. Jonat, W. Eiermann, M. Geberth, U.-S. Albert, G. Gademann, B. Conrad, K. Stahl, G. von Minckwitz, et al. Tamoxifen Versus Control After Adjuvant, Risk-Adapted Chemotherapy in Postmenopausal, Receptor-Negative Patients With Breast Cancer: A Randomized Trial (GABG-IV D-93)--The German Adjuvant Breast Cancer Group J. Clin. Oncol., November 1, 2005; 23(31): 7842 - 7848. [Abstract] [Full Text] [PDF]

				M. King, I. Nazareth, F. Lampe, P. Bower, M. Chandler, M. Morou, B. Sibbald, and R. Lai Impact of Participant and Physician Intervention Preferences on Randomized Trials: A Systematic Review JAMA, March 2, 2005; 293(9): 1089 - 1099. [Abstract] [Full Text] [PDF]

				A. H. Partridge, P. S. Wang, E. P. Winer, and J. Avorn Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer J. Clin. Oncol., February 15, 2003; 21(4): 602 - 606. [Abstract] [Full Text] [PDF]

				P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot, A. Bremond, M. Namer, S. Schraub, M.-J. Goudier, J. Mihura, A. Monnier, et al. Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial J. Clin. Oncol., January 15, 2003; 21(2): 298 - 305. [Abstract] [Full Text] [PDF]

				A. H. Partridge, J. Avorn, P. S. Wang, and E. P. Winer Adherence to Therapy With Oral Antineoplastic Agents J Natl Cancer Inst, May 1, 2002; 94(9): 652 - 661. [Abstract] [Full Text] [PDF]

				C. Schmoor, W. Sauerbrei, G. Bastert, and M. Schumacher Role of Isolated Locoregional Recurrence of Breast Cancer: Results of Four Prospective Studies J. Clin. Oncol., April 1, 2000; 18(8): 1696 - 1708. [Abstract] [Full Text] [PDF]

				W. Sauerbrei, G. Bastert, H. Bojar, C. Beyerle, R. L. A. Neumann, C. Schmoor, and M. Schumacher Randomized 2 2 Trial Evaluating Hormonal Treatment and the Duration of Chemotherapy in Node-Positive Breast Cancer Patients: An Update Based on 10 Years’ Follow-Up J. Clin. Oncol., January 5, 2000; 18(1): 94 - 94. [Abstract] [Full Text] [PDF]